Home / Japan / Oncolys BioPharma Inc.
Oncolys BioPharma Inc.
Short position disclosed on November 2, 2026.
10.84% of the capital sold short
6 disclosing funds
180 disclosures on record
Evolution of the disclosed total
0%5%10%15%
Aug 23Sep 11Sep 30Oct 19
Open positions
| Fund | Twelve months | % of capital | Over the year | Since |
|---|---|---|---|---|
| Barclays Capital Securities Ltd | 3.11% | -1.54 pt | October 30, 2026 | |
| Goldman Sachs International | 2.34% | new | October 30, 2026 | |
| Citigroup Global Markets Limited | 1.96% | new | November 2, 2026 | |
| モルガン・スタンレーmufg証券株式会社 | 1.85% | -4.42 pt | November 2, 2026 | |
| UBS AG | 0.90% | -0.42 pt | October 30, 2026 | |
| Nomura International plc | 0.68% | new | November 2, 2026 |
Get the moves on Oncolys BioPharma Inc. by mail, at most once a day.
There is no account to create. You give an address, you confirm it through a link, and every message contains a link to stop.
History of disclosures
Download 180 filings as CSV Columns: Date, Fund, Market, Disclosed position, Unit, End date. The other formats
Other companies sold short in Japan
- FLIGHT SOLUTIONS Inc. 12.10% of the capital sold short
- Datasection Inc. 11.70% of the capital sold short
- QD Laser,Inc. 11.57% of the capital sold short
- GNI Group Ltd. 10.86% of the capital sold short
- Metaplanet Inc. 10.27% of the capital sold short
- AIMECHATEC,Ltd. 9.68% of the capital sold short
- ReYuu Japan Inc. 9.50% of the capital sold short
- Kasumigaseki Capital Co.,Ltd. 9.49% of the capital sold short
- KLab Inc. 8.85% of the capital sold short
- Astroscale Holdings Inc. 8.80% of the capital sold short
- Hutzper Inc. 8.70% of the capital sold short
- eole Inc. 8.08% of the capital sold short
Cite this page
The figure comes from the regulator register, not from this site. Quoting both lets your reader check it.
QuiVad, Oncolys BioPharma Inc., source JPX, data as at November 2, 2026, https://www.quivad.com/action/oncolys-biopharma-inc?page=4